Sesen Bio to Host Conference Call to Review Fourth Quarter & Full-Year 2018 Financial Results & Additional Preliminary Data f...
25 Fevereiro 2019 - 6:20PM
Business Wire
Sesen Bio (Nasdaq: SESN), a late-stage clinical company
developing targeted fusion protein therapeutics for the treatment
of people with cancer, today announced that Company management will
host a conference call and webcast on Monday, March 4, 2019 at 8:00
a.m. EST to review operating results for the fourth quarter and
full year ended December 31, 2018 and new, preliminary analyses
from the Phase 3 VISTA trial of Vicinium® for patients with
high-risk non-muscle invasive bladder cancer who have been
previously treated with bacillus Calmette-Guérin.
To participate in the conference call, please dial (844)
831-3025 (domestic) or (315) 625-6887 (international) and refer to
conference ID 2179668. The webcast can be accessed in the Investor
Relations section of the Company's website at www.sesenbio.com. The
replay of the webcast will be available in the investor section of
the Company’s website at www.sesenbio.com for 60 days following the
call.
About Sesen BioSesen Bio, Inc. is a late-stage clinical
company advancing targeted fusion protein therapeutics for the
treatment of patients with cancer. The Company’s lead program,
Vicinium®, also known as VB4-845, is currently in a Phase 3
registration trial, the VISTA trial, for the treatment of
high-risk, BCG un-responsive non-muscle invasive bladder cancer.
Updated twelve-month data from the trial are anticipated in
mid-2019. Vicinium incorporates a tumor-targeting antibody fragment
and a protein cytotoxic payload into a single protein molecule
designed to selectively and effectively kill cancer cells, while
minimizing toxicity to non-cancerous bladder cells. For more
information, please visit the Company’s website at
www.sesenbio.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190225006040/en/
Erin Clark, Executive Director, Strategic Planning &
Investor Relationserin.clark@sesenbio.com
Sesen Bio (NASDAQ:SESN)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Sesen Bio (NASDAQ:SESN)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024